About the COMBO Dual Therapy Stent<\/b><\/p> \n
The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven Pro-Healing Technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that is completely dissipated within 90 days.<\/p> \n
OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.<\/p> \n
About OrbusNeich<\/b><\/p> \n
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC<\/span>. OrbusNeich is headquartered in Hong Kong<\/span> and has operations in Shenzhen, China<\/span>; Fort Lauderdale, Fla.<\/span>; Hoevelaken, The Netherlands<\/span>; and Tokyo, Japan<\/span>. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com<\/a>.<\/p>"]; $("#dvExtra").html(content_array[0]);})();